# IFN-beta 1b and Remdesivir for COVID19

> **NCT04647695** · PHASE2 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 100 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Interferon beta-1b
- **DRUG:** Remdesivir

## Key facts

- **NCT ID:** NCT04647695
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-20
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04647695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04647695, "IFN-beta 1b and Remdesivir for COVID19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04647695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*